Icosagen AS, an Estonian-based biopharmaceutical innovator, has reached a $18 million financing deal with the European Investment Bank (EIB), to further strengthen its drug discovery, development and production services. The agreement is backed by the InvestEU program.  The funds are part of Icosagen’s $40 million investment into expanding its contract research and development capabilities as well as into a new current good manufacturing practice (cGMP) facility to produce drugs for clinic...